MarginsXMarginsX
Home › Markets › Health Care › AUTL

Autolus Therapeutics plc American Depositary Share (AUTL)

AUTL trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.14
-2.56% on the day
Market cap
$303.6M
Small cap
Revenue · 2025
$75.4M
+644.9% on 2024
Net income · 2025
-$287.5M
-381.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1730463/000173046326000038/0001730463-26-000038-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerAUTL on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited Kingdom
IPO year2018
SEC CIK0001730463
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inUnited Kingdom

Financials · 2025

LineValue
Revenue$75.4M
Net income-$287.5M
Operating income-$270.5M
Net margin-381.4%
Operating margin-358.9%
Revenue growth+644.9%
Cash$104.1M
Total assets$589.1M
P/E (computed)Net income was not positive
P/S (computed)4.0×

Warning signs

Cash runway
16.7 months
$245.4M cash at September 30, 2026
Share count, 1 year
+0.1%
2025-11-11 to 2026-11-09 · +53.1% over 3 years
Going-concern doubt
No
10-Q filed November 10, 2026
Insider net buying, 12 months
-$16K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"Accordingly, management has concluded that there are no conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that these unaudited condensed consolidated financial statements are issued."
10-Q 2026-11-10
Cash and burn$245.4M cash; operating cash flow -$44.1M a quarter.Report 2026-09-30
Shares outstanding266,340,330 (2026-11-09); 266,143,286 a year earlier; 173,989,157 three years earlier.Cover page 2026-11-09
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months3 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-09-14
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Reading, United Kingdom; changed auditors 1 time in 24 months8-K 4.01 2026-04-16
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $16K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$41.2M-$55.1M-$18.5M$245.4MNo debt tags$137.4M10-Q 2026-11-10
Q2 2026
2026-06-30
$45.7M-$39.1M-$25.1M$171.4MNo debt tags$117.4M10-Q 2026-08-11
Q1 2026
2026-03-31
$26.2M-$71.6M-$65.3M$130.9MNo debt tags$92.6M10-Q 2026-05-14
Q4 2025
2025-12-31
$24.3M-$90.3M-$67.3M$104.1MNo debt tags$75.4M10-K 2026-03-27
Q3 2025
2025-09-30
$21.2M-$79.1M-$67.9M$86.1MNo debt tags$51.1M10-Q 2026-11-10
Q2 2025
2025-06-30
$20.9M-$47.9M-$72.8M$123.8MNo debt tags$29.9M10-Q 2026-08-11
Q1 2025
2025-03-31
$9.0M-$70.2M-$75.6M$95.8MNo debt tags$9.0M10-Q 2025-05-08
Q4 2024
2024-12-31
$29K-$27.6M-$37.9M$227.4MNo debt tags$10.1M10-K 2026-03-27

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-09-22
Latest annual report10-K2026-03-27
Latest quarterly / interim10-Q2026-11-10
Latest current report8-K2026-11-10

Source: SEC EDGAR submissions feed, 343 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-8.6%
1 month-27.8%
3 months-47.3%
Year to date-41.2%
1 year-8.6%
From 52-week high-53.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
KYTXKyverna Therapeutics Inc.$4.76-5.74%$300.9M
IPSCCentury Therapeutics Inc.$1.64-0.61%$297.8M
TRXBTRex Bio Inc.$10.77-21.21%$295.6M
AGMBAgomAb Therapeutics NV$5.97-6.13%$294.0M
PROKProKidney Corp.$1.04-0.48%$314.5M
EIKNEikon Therapeutics Inc.$5.38-9.95%$291.8M
SCTXScribe Therapeutics Inc.$15.37-6.05%$291.1M
XFORX4 Pharmaceuticals Inc.$2.83-9.29%$289.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier